<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160991</url>
  </required_header>
  <id_info>
    <org_study_id>DeuOlanAmi</org_study_id>
    <nct_id>NCT01160991</nct_id>
  </id_info>
  <brief_title>Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism</brief_title>
  <official_title>Effects of the Serotonin 2A Receptor on Insulin Sensitivity and Secretion: a Double-blind Controlled Comparison of Olanzapine vs. Amisulpride:</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Institute of Mental Health, Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Institute of Mental Health, Mannheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients suffering from schizophrenia have a high risk to become obese and develop diabetes.
      Risk of obesity is particularly high with some newer schizophrenia drugs, such as clozapine
      or olanzapine. These drugs are called atypical drugs and exert their action in part by
      occupying receptors for serotonin, particularly the 5HT2A receptor subtype. This receptor may
      also interfere with glucose metabolism and insulin action. The purpose of this study is to
      compare an atypical antipsychotic drugs, olanzapine, which acts by occupying the 5HT2A
      receptor, to another antipsychotic drug, amisulpride, which mainly acts through the dopamine
      pathway. Healthy volunteers are recruited and asked to take a single dose of each drug and of
      placebo on separate days. Then, a combined glucose clamp study will be performed in order to
      test the effects of these drugs on insulin sensitivity and insulin secretion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      10 male healthy volunteers are recruited. After informed consent, they are admitted to the
      study ward at 10:00 p.m. prior to the study day and kept fasting until the next morning. At
      8:00 a.m. they receive their study medication (olanzapine, amisulpride or placebo).
      Subsequently, measurements of insulin sensitivity and insulin secretion are performed by
      euglycemic hyperinsulinemic clamp technique followed by hyperglycemic clamp.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>90 thru 120 min after application of study drug</time_frame>
    <description>m-value during euglycemic glucose clamp (glucose infusion rate divided by time and body weight)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pancratic c-peptide secretion</measure>
    <time_frame>120 thru 180 minutes after administration of study drug</time_frame>
    <description>C-peptide measured 4 times during hyperglycemic clamp period at time 0 min (prior to glucose bolus), 5 min, 10 min and 60 min after glucose bolus</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Diabetes</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Amisulpride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of amisulpride 200 mg p.o. given at 8:00 a.m.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of olanzapine 10 mg p.o. given at 8:00 a.m.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules are given at 8:00 a.m. Procedures are performed as described above.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Glucose clamp technique</intervention_name>
    <description>euglycemic hyperinsulinemic clamp with target blood glucose of 90 mg/dl (5 mmol/l), followed by hyperglycemic clamp, target blood glucose of 180 mg/dl (10 mmol/l) for measurement of insulin sensitivity and insulin secretion</description>
    <arm_group_label>Amisulpride</arm_group_label>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amisulpride</intervention_name>
    <description>Single dose of amisulpride 200 mg p.o. given at 8:00 a.m.</description>
    <arm_group_label>Amisulpride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Single dose of olanzapine 10 mg p.o. given at 8:00 a.m.</description>
    <arm_group_label>Olanzapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules are given at 8:00 a.m.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male volunteers

          -  written informed consent

        Exclusion Criteria:

          -  BMI &gt; 30 kg/mÂ²

          -  Diabetes mellitus

          -  Hypertension

          -  Treatment with drugs interfering with lipid or glucose metabolism (e.g. statins, oral
             antidiabetic drugs, glucocorticoids)

          -  History of seizures
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Kopf, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Institute of Mental Health, Mannheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Institute of Mental Health</name>
      <address>
        <city>Mannheim</city>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2010</study_first_posted>
  <last_update_submitted>August 2, 2010</last_update_submitted>
  <last_update_submitted_qc>August 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Michael Deuschle</name_title>
    <organization>Central Institute of Mental Health</organization>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>olanzapine</keyword>
  <keyword>atypical antipsychotic drugs</keyword>
  <keyword>amisulpride</keyword>
  <keyword>diabetes</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>insulin secretion</keyword>
  <keyword>glucose</keyword>
  <keyword>euglycemic hyperinsulinemic clamp</keyword>
  <keyword>hyperglycemic clamp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Sultopride</mesh_term>
    <mesh_term>Sulpiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

